Kim Soo-Joong, Giugliano Robert P, Jang Ik-Kyung
Department of Cardiology, College of Medicine, Kyung Hee University Medical Center, Seoul, Korea.
Coron Artery Dis. 2011 Mar;22(1):113-21. doi: 10.1097/01.mca.0000394697.74220.cd.
Pharmacological adjuvant therapies to protect against procedure-related thrombotic complication are indispensable during percutaneous coronary intervention. In addition to antiplatelet therapy, use of anticoagulants to prevent acute thrombotic complication during percutaneous coronary intervention is essential. Besides unfractionated heparin (UFH), new anticoagulants have been developed and compared with UFH. Low-molecular weight heparins, direct thrombin inhibitors (e.g. bivalirudin), and recently developed agents such as fondaparinux (a factor Xa inhibitor) provide new alternatives to conventional UFH.
在经皮冠状动脉介入治疗期间，用于预防与手术相关血栓形成并发症的药理学辅助治疗不可或缺。除抗血小板治疗外，在经皮冠状动脉介入治疗期间使用抗凝剂预防急性血栓形成并发症至关重要。除了普通肝素（UFH）外，新型抗凝剂已被研发出来并与UFH进行了比较。低分子量肝素、直接凝血酶抑制剂（如比伐卢定）以及最近研发的药物如磺达肝癸钠（一种Xa因子抑制剂）为传统UFH提供了新的替代选择。
